The Medical Supply Chain Resiliency Act, also known as Bill 118 hr 4307, is a piece of legislation introduced in the US Congress aimed at strengthening the country's medical supply chain. The bill focuses on ensuring that the United States is better prepared to handle future public health emergencies, such as pandemics or natural disasters.
One of the key provisions of the bill is the establishment of a task force that will be responsible for conducting a comprehensive review of the medical supply chain. This task force will assess the current vulnerabilities in the supply chain and make recommendations for improvements to ensure that the country is better equipped to respond to emergencies.
Additionally, the bill includes measures to increase domestic production of critical medical supplies. This includes providing incentives for manufacturers to produce these supplies in the United States, as well as investing in research and development to improve the efficiency and effectiveness of domestic production.
The Medical Supply Chain Resiliency Act also aims to improve coordination and communication between federal, state, and local governments, as well as private sector stakeholders, to ensure a more cohesive and effective response to public health emergencies.
Overall, the goal of the bill is to enhance the resiliency of the medical supply chain in the United States, so that the country is better prepared to respond to future public health crises.